Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).

Authors :: Mateos, Maria-Victoria
Robak, Pawel
Hus, Marek
Xia, Zhongjun
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
Hajek, Roman
Kim, Kihyun
Dimopoulos, Meletios A.
Cerchione, Claudio
Riccio, Antonio
McKeown, Astrid
Rogers, Rachel
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Hungria, Vania
Source :: Journal of Clinical Oncology; 2024 Supplement36, Vol. 42, p439572-439572, 1p
Publication Year :: 2024

Full Text Access

Tools